Cargando…

Increased Risk of Site-Specific Cancer in People with Type 2 Diabetes: A National Cohort Study

A retrospective cohort design was used with the objective to evaluate cancer risk among people with type 2 diabetes mellitus (T2DM) in Lithuania. The cohort was established by identifying all patients with the first diagnosis of T2DM in the National Health Insurance Fund database during 2000–2012. C...

Descripción completa

Detalles Bibliográficos
Autores principales: Linkeviciute-Ulinskiene, Donata, Patasius, Ausvydas, Zabuliene, Lina, Stukas, Rimantas, Smailyte, Giedre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6982113/
https://www.ncbi.nlm.nih.gov/pubmed/31905811
http://dx.doi.org/10.3390/ijerph17010246
_version_ 1783491240640118784
author Linkeviciute-Ulinskiene, Donata
Patasius, Ausvydas
Zabuliene, Lina
Stukas, Rimantas
Smailyte, Giedre
author_facet Linkeviciute-Ulinskiene, Donata
Patasius, Ausvydas
Zabuliene, Lina
Stukas, Rimantas
Smailyte, Giedre
author_sort Linkeviciute-Ulinskiene, Donata
collection PubMed
description A retrospective cohort design was used with the objective to evaluate cancer risk among people with type 2 diabetes mellitus (T2DM) in Lithuania. The cohort was established by identifying all patients with the first diagnosis of T2DM in the National Health Insurance Fund database during 2000–2012. Cancer cases were identified by record linkage with the Lithuanian Cancer Registry. Standardized incidence ratios (SIRs) were calculated. Of the 127,290 people that were included, 5959 cases of cancer in men and 6661 cancer cases in women with T2DM were observed. A statistically significant increase in risk for all cancer sites was observed in women, SIR 1.16 (95% CI 1.14–1.19), but not in men, SIR 1.00 (95% CI 0.98–1.03). Among males, a significant increase of liver (SIR 2.11, 95% CI 1.79–2.49]), pancreas (SIR 1.77, 95% CI 1.57–1.99), kidney (SIR 1.46 95% CI 1.31–1.62), thyroid (SIR 1.83, 95% CI 1.32–2.54), colorectal (SIR 1.23, 95% CI 1.14–1.31]), skin melanoma (SIR 1.40, 95% CI 1.11–1.76), and non–melanoma skin (SIR 1.14, 95% CI 1.05–1.23) cancer was observed. For females with T2DM, a significant increase in risk of cancer of the liver (SIR 1.45, 95% CI 1.17–1.79), pancreas (SIR 1.74, 95% CI 1.56–1.93), kidney (SIR = 1.43, 95% CI 1.28–1.60), thyroid (SIR = 1.40, 95% CI 1.22–1.62), breast (SIR = 1.24, 95% CI 1.17–1.31), and corpus uteri (SIR 2.07, 95% CI 1.93–2.21) was observed. In conclusion, people with T2DM in Lithuania had an increased risk of site-specific cancer.
format Online
Article
Text
id pubmed-6982113
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-69821132020-02-07 Increased Risk of Site-Specific Cancer in People with Type 2 Diabetes: A National Cohort Study Linkeviciute-Ulinskiene, Donata Patasius, Ausvydas Zabuliene, Lina Stukas, Rimantas Smailyte, Giedre Int J Environ Res Public Health Article A retrospective cohort design was used with the objective to evaluate cancer risk among people with type 2 diabetes mellitus (T2DM) in Lithuania. The cohort was established by identifying all patients with the first diagnosis of T2DM in the National Health Insurance Fund database during 2000–2012. Cancer cases were identified by record linkage with the Lithuanian Cancer Registry. Standardized incidence ratios (SIRs) were calculated. Of the 127,290 people that were included, 5959 cases of cancer in men and 6661 cancer cases in women with T2DM were observed. A statistically significant increase in risk for all cancer sites was observed in women, SIR 1.16 (95% CI 1.14–1.19), but not in men, SIR 1.00 (95% CI 0.98–1.03). Among males, a significant increase of liver (SIR 2.11, 95% CI 1.79–2.49]), pancreas (SIR 1.77, 95% CI 1.57–1.99), kidney (SIR 1.46 95% CI 1.31–1.62), thyroid (SIR 1.83, 95% CI 1.32–2.54), colorectal (SIR 1.23, 95% CI 1.14–1.31]), skin melanoma (SIR 1.40, 95% CI 1.11–1.76), and non–melanoma skin (SIR 1.14, 95% CI 1.05–1.23) cancer was observed. For females with T2DM, a significant increase in risk of cancer of the liver (SIR 1.45, 95% CI 1.17–1.79), pancreas (SIR 1.74, 95% CI 1.56–1.93), kidney (SIR = 1.43, 95% CI 1.28–1.60), thyroid (SIR = 1.40, 95% CI 1.22–1.62), breast (SIR = 1.24, 95% CI 1.17–1.31), and corpus uteri (SIR 2.07, 95% CI 1.93–2.21) was observed. In conclusion, people with T2DM in Lithuania had an increased risk of site-specific cancer. MDPI 2019-12-30 2020-01 /pmc/articles/PMC6982113/ /pubmed/31905811 http://dx.doi.org/10.3390/ijerph17010246 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Linkeviciute-Ulinskiene, Donata
Patasius, Ausvydas
Zabuliene, Lina
Stukas, Rimantas
Smailyte, Giedre
Increased Risk of Site-Specific Cancer in People with Type 2 Diabetes: A National Cohort Study
title Increased Risk of Site-Specific Cancer in People with Type 2 Diabetes: A National Cohort Study
title_full Increased Risk of Site-Specific Cancer in People with Type 2 Diabetes: A National Cohort Study
title_fullStr Increased Risk of Site-Specific Cancer in People with Type 2 Diabetes: A National Cohort Study
title_full_unstemmed Increased Risk of Site-Specific Cancer in People with Type 2 Diabetes: A National Cohort Study
title_short Increased Risk of Site-Specific Cancer in People with Type 2 Diabetes: A National Cohort Study
title_sort increased risk of site-specific cancer in people with type 2 diabetes: a national cohort study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6982113/
https://www.ncbi.nlm.nih.gov/pubmed/31905811
http://dx.doi.org/10.3390/ijerph17010246
work_keys_str_mv AT linkeviciuteulinskienedonata increasedriskofsitespecificcancerinpeoplewithtype2diabetesanationalcohortstudy
AT patasiusausvydas increasedriskofsitespecificcancerinpeoplewithtype2diabetesanationalcohortstudy
AT zabulienelina increasedriskofsitespecificcancerinpeoplewithtype2diabetesanationalcohortstudy
AT stukasrimantas increasedriskofsitespecificcancerinpeoplewithtype2diabetesanationalcohortstudy
AT smailytegiedre increasedriskofsitespecificcancerinpeoplewithtype2diabetesanationalcohortstudy